---
title: "Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Phase of product development"
description: "Formulary evidence on Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Phase of product development. Topics: Investigational status, Regulatory status: Submission planned; NDA submission planned for 2027, Launch: Anticipated in 2028, OPERA-01 top-line data expected in the first quarter of 2027 (November 2026), and 18 further topics. 22 evidence topics quoted from 15 sources."
canonical: "https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/product-information-and-disease-description/phase-of-product-development"
published: "2026-11-15T20:23:25-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Phase of product development

<a id="heading-2.1.1"></a>

## 2.1.1 Phase of Product Development

<a id="topic-2.1.1-1"></a>

### Investigational status

> “We do not have any product candidates approved for commercial sale, and we have not generated any revenue from product sales.”

Source: [Olema Oncology Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1750284/000119312526454421/olma-20260930.htm)

<a id="topic-2.1.1-2"></a>

### Regulatory status: Submission planned; NDA submission planned for 2027

> “In November 2023, we initiated OPERA-01, our pivotal Phase 3 clinical trial of palazestrant as a monotherapy in second/third-line ER+/HER2- MBC. We have completed enrollment and anticipate top-line results for this trial in the first quarter of 2027, expect to submit the new drug application (NDA) in 2027”

Source: [Olema Oncology Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1750284/000119312526454421/olma-20260930.htm)

> “2027: Anticipated submission of New Drug Application for potential approval of palazestrant as a monotherapy in 2/3L ER+/HER2-MBC and preparations for commercial launch”

Source: [Olema Oncology corporate presentation (2026)](https://ir.olema.com/static-files/0669229e-3ae2-4bed-a1ce-308627866d06)

<a id="topic-2.1.1-3"></a>

### Launch: Anticipated in 2028

> “if successful, anticipate potential U.S. Food and Drug Administration (FDA) approval and commercial launch in 2028.”

Source: [Olema Oncology Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1750284/000119312526454421/olma-20260930.htm)

> “2028: Potential FDA approval and U.S. commercial launch of palazestrant”
> “Planning for commercial launch of palazestrant as a monotherapy in 2/3L ER+/HER2- MBC anticipated in 2028”

Source: [Olema Oncology corporate presentation (2026)](https://ir.olema.com/static-files/0669229e-3ae2-4bed-a1ce-308627866d06)

<a id="topic-2.1.1-4"></a>

### OPERA-01 top-line data expected in the first quarter of 2027 (November 2026)

> “On track to announce top-line data from the pivotal Phase 3 OPERA-01 trial in the first quarter of 2027”
> “Beyond preparing for the potential approval and commercialization of palazestrant”

Source: [Olema Oncology third quarter 2026 results announcement (2026)](https://ir.olema.com/news-releases/news-release-details/olema-oncology-reports-third-quarter-2026-financial-and)

<a id="topic-2.1.1-5"></a>

### OPERA-01 enrollment completed and top-line timing moved to the first quarter of 2027 (August 2026)

> “Completed enrollment in the pivotal Phase 3 OPERA-01 trial; top-line data are now expected in the first quarter of 2027”
> “Importantly, enrollment in our pivotal OPERA-01 Phase 3 trial is complete and we now expect to report top-line data in the first quarter of 2027”

Source: [Olema Oncology second quarter 2026 results announcement (2026)](https://ir.olema.com/news-releases/news-release-details/olema-oncology-reports-second-quarter-2026-financial-and)

<a id="topic-2.1.1-6"></a>

### Earlier guidance: top-line data in fall 2026 and launch in 2027 (May 2026)

> “Report top-line data from the pivotal Phase 3 OPERA-01 trial of palazestrant as a monotherapy in second- and third-line ER+/HER2- metastatic breast cancer in the fall of 2026.”
> “we believe that we are well-positioned to continue our transformation into a fully integrated oncology company with our first anticipated commercial launch next year.”

Source: [Olema Oncology first quarter 2026 results announcement (2026)](https://ir.olema.com/news-releases/news-release-details/olema-oncology-reports-first-quarter-2026-financial-and)

<a id="topic-2.1.1-7"></a>

### Earlier guidance: top-line data in fall 2026, NDA in 2027, and approval and launch in late 2027 (March 2026)

> “We anticipate top-line results for this trial in the fall of 2026, expect to submit the NDA in 2027, and, if successful, anticipate potential U.S. Food and Drug Administration (FDA) approval and commercial launch in late 2027.”

Source: [Olema Oncology Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1750284/000119312526107169/olma-20251231.htm)

> “Transformation into a fully-integrated oncology company underway in preparation for the Company’s first potential commercial launch in late 2027”

Source: [Olema Oncology fourth quarter and full year 2025 results announcement (2026)](https://ir.olema.com/news-releases/news-release-details/olema-oncology-reports-fourth-quarter-and-full-year-2025)

<a id="topic-2.1.1-8"></a>

### Earlier guidance: top-line data in the second half of 2026 (August 2025)

> “OPERA-01 enrollment ongoing with top-line data expected in the second half of 2026; OPERA-02 on track to initiate in Q3 2025”

Source: [Olema Oncology second quarter 2025 results announcement (2025)](https://ir.olema.com/news-releases/news-release-details/olema-oncology-reports-second-quarter-2025-financial-and)

<a id="topic-2.1.1-9"></a>

### Earlier guidance: top-line data in 2026 and launch in 2027 (May 2025)

> “we are focused on rapidly advancing our OPERA-01 and OPERA-02 pivotal trials with top-line data from OPERA-01 anticipated in 2026 and a potential commercial launch in 2027.”

Source: [Olema Oncology dose selection announcement (2025)](https://ir.olema.com/news-releases/news-release-details/olema-oncology-announces-palazestrant-dose-selection-and-trial)

<a id="topic-2.1.1-10"></a>

### Earlier guidance: top-line data in 2026 (December 2024)

> “We remain on track to share topline data from OPERA-01 in 2026”

Source: [Olema Oncology Novartis OPERA-02 agreement announcement (2024)](https://ir.olema.com/news-releases/news-release-details/olema-oncology-announces-new-clinical-trial-collaboration-and)

<a id="topic-2.1.1-11"></a>

### Fast Track designation, July 2022

> “July 21, 2022”
> “today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to OP-1250”
> “for the treatment of ER-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer that has progressed following one or more lines of endocrine therapy with at least one line given in combination with a cyclin-dependent kinase (CDK) 4/6 inhibitor.”

Source: [Olema Oncology Fast Track designation announcement (2022)](https://ir.olema.com/news-releases/news-release-details/olema-oncology-receives-fda-fast-track-designation-op-1250)

<a id="topic-2.1.1-12"></a>

### Fast Track designation: eligibility for priority review, accelerated approval, and rolling submission

> “In July 2022, we were granted FDA Fast Track designation for palazestrant for ER+/HER2- metastatic breast cancer that has progressed following one or more lines of endocrine therapy with at least one line given in combination with a CDK4/6 inhibitor.”
> “NDAs submitted for Fast Track designated drugs may qualify for priority review, accelerated approval and rolling submission under the policies and procedures offered by the FDA, but the Fast Track designation does not assure any such qualification or ultimate marketing approval by the FDA.”

Source: [Olema Oncology Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1750284/000119312526454421/olma-20260930.htm)

<a id="topic-2.1.1-13"></a>

### Dose of 90 mg once daily selected in alignment with FDA, May 2025

> “90 mg once-daily palazestrant dose selected for Part 2 of the Phase 3 OPERA-01 monotherapy trial and for the Phase 3 OPERA-02 combination trial with ribociclib”
> “today announced it has aligned with the U.S. Food and Drug Administration (FDA) to select 90 mg of palazestrant as the dose for Part 2 of the ongoing registrational Phase 3 OPERA-01 trial in second- and third-line estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) metastatic breast cancer.”
> “The FDA also selected 90 mg of palazestrant in combination with the approved dose of CDK4/6 inhibitor ribociclib for the pivotal Phase 3 OPERA-02 trial in frontline ER+/HER2- metastatic breast cancer.”

Source: [Olema Oncology dose selection announcement (2025)](https://ir.olema.com/news-releases/news-release-details/olema-oncology-announces-palazestrant-dose-selection-and-trial)

<a id="topic-2.1.1-14"></a>

### OPERA-01: first participant dosed in November 2023

> “OPERA-01 trials-in-progress poster outlines Phase 3 trial design; clinical sites activated and enrolling with first patient dosed in November 2023”

Source: [Olema Oncology SABCS 2023 combination results announcement (2023)](https://ir.olema.com/news-releases/news-release-details/olema-oncology-announces-palazestrant-demonstrates-attractive)

<a id="topic-2.1.1-15"></a>

### OPERA-02: initiated in the third quarter of 2025

> “In the third quarter of 2025, we initiated OPERA-02, the pivotal Phase 3 clinical trial of palazestrant in combination with ribociclib in patients with frontline advanced or metastatic ER+/HER2- breast cancer.”
> “The trial is currently enrolling, and is expected to enroll approximately 1,000 patients, half of whom will receive palazestrant plus ribociclib; the other half will receive letrozole, a standard-of-care aromatase inhibitor, plus ribociclib.”

Source: [Olema Oncology Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1750284/000119312526107169/olma-20251231.htm)

> “Initiated OPERA-02 Phase 3 trial of palazestrant in combination with ribociclib in frontline ER+/HER2- metastatic breast cancer”

Source: [Olema Oncology third quarter 2025 results announcement (2025)](https://ir.olema.com/news-releases/news-release-details/olema-oncology-reports-third-quarter-2025-financial-and)

<a id="topic-2.1.1-16"></a>

### OPERA-02: enrollment ongoing, November 2026

> “Continued strong enrollment in the pivotal Phase 3 OPERA-02 trial and the Phase 1b/2 study of OP-3136”
> “It is being evaluated as a single agent in the ongoing pivotal Phase 3 clinical trial, OPERA-01, and in combination with ribociclib in the ongoing pivotal Phase 3 clinical trial, OPERA-02. Palazestrant is also being evaluated in multiple Phase 1/2 studies in combination with ribociclib, palbociclib, alpelisib, everolimus, and atirmociclib.”

Source: [Olema Oncology third quarter 2026 results announcement (2026)](https://ir.olema.com/news-releases/news-release-details/olema-oncology-reports-third-quarter-2026-financial-and)

<a id="topic-2.1.1-17"></a>

### Stage of development by setting

> “Monotherapy: Phase 3”
> “In Combination: Phase 3; multiple studies in Phase 1/2”

Source: [Olema Oncology corporate presentation (2026)](https://ir.olema.com/static-files/0669229e-3ae2-4bed-a1ce-308627866d06)

<a id="topic-2.1.1-18"></a>

### Partnership: Novartis clinical collaboration for ribociclib and alpelisib combinations (2020, amended 2022 and 2023)

> “Olema first signed a clinical collaboration and supply agreement with Novartis in July 2020, the agreement was amended and restated in January 2022, and focuses on the evaluation of the safety, tolerability and efficacy of palazestrant in combination with Novartis’ proprietary cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor ribociclib and/or Novartis’ proprietary phosphatidylinositol 3-kinase (PI3Ka) inhibitor alpelisib in patients with metastatic ER+ breast cancer.”
> “The amendment adds approximately 30 patients to be enrolled in the cohort expansion phase of the palazestrant clinical study in combination with ribociclib.”

Source: [Olema Oncology Novartis collaboration expansion announcement (2023)](https://ir.olema.com/news-releases/news-release-details/olema-oncology-announces-expansion-collaboration-agreement)

<a id="topic-2.1.1-19"></a>

### Partnership: Novartis ribociclib supply for OPERA-02 (2024)

> “Under the terms of the agreement, Novartis will provide Olema with ribociclib drug supply for the planned, Olema-sponsored, Phase 3 OPERA-02 trial of palazestrant in combination with ribociclib in ER+/HER2- frontline advanced or metastatic breast cancer. All clinical data and inventions from the trial will be jointly owned while Olema maintains global commercial and marketing rights to palazestrant.”

Source: [Olema Oncology Novartis OPERA-02 agreement announcement (2024)](https://ir.olema.com/news-releases/news-release-details/olema-oncology-announces-new-clinical-trial-collaboration-and)

<a id="topic-2.1.1-20"></a>

### Partnership: Novartis right of first negotiation

> “We granted Novartis a right of first negotiation with respect to (a) the grant to any person or entity any right, license or sublicense to exploit palazestrant, in any field or territory, other than to third party service providers, or (b) the sale or other transfer to any person or entity of palazestrant and any related assets, each referred to herein as an Olema Compound Transaction.”

Source: [Olema Oncology Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1750284/000119312526107169/olma-20251231.htm)

<a id="topic-2.1.1-21"></a>

### Partnership: Pfizer palbociclib (2020) and atirmociclib (2025) agreements

> “Under the terms of the agreement, Pfizer will supply atirmociclib for use in the Phase 1b/2 study and Olema will lead the conduct of the study. All clinical data and inventions relating to the combined use of atirmociclib and palazestrant resulting from the study will be jointly owned, with Olema maintaining full global commercial and marketing rights to palazestrant.”
> “This announcement represents Olema’s second clinical trial agreement with Pfizer. The companies’ previous agreement was established in November 2020 to evaluate palazestrant in combination with palbociclib (IBRANCE®) in patients with recurrent, locally advanced or metastatic ER+/HER2- breast cancer.”

Source: [Olema Oncology Pfizer atirmociclib agreement announcement (2025)](https://ir.olema.com/news-releases/news-release-details/olema-oncology-announces-new-clinical-trial-agreement-pfizer)

<a id="topic-2.1.1-22"></a>

### Patents: composition of matter to 2036; pending applications to 2040 to 2046

> “The 20-year term for these patents expires in 2036. In the United States, it is uncertain whether any PTE will be available, and if so, how much.”
> “Additional patent applications are pending, including applications that relate to dosing regimens and treatment of particular cancers, formulations, and additional combination therapies, including combination therapy with ribociclib, among other patent applications, and, if granted, will have 20-year terms that expire between 2040 and 2046.”

Source: [Olema Oncology Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1750284/000119312526107169/olma-20251231.htm)

<a id="topic-2.1.1-23"></a>

### Regulatory status outside the United States

No evidence found.

## Related pages
- [Palazestrant (OP-1250): Previously treated ER-positive HER2-negative advanced or metastatic breast cancer](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Terms and abbreviations](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/terms-and-abbreviations.md)
- [Palazestrant (OP-1250): Previously treated ER-positive HER2-negative advanced or metastatic breast cancer](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/executive-summary) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/executive-summary.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Product information and disease description](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/product-information-and-disease-description.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Clinical evidence](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/clinical-evidence.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Economic information and modeling report](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/economics) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/economics.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: References](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/references) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/references.md)
